Browse

Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival

DC Field Value Language
dc.contributor.authorKim, J. -S.-
dc.contributor.authorKim, M. -A.-
dc.contributor.authorKim, T. M.-
dc.contributor.authorLee, S. -H.-
dc.contributor.authorKim, D. -W.-
dc.contributor.authorIm, S. -A.-
dc.contributor.authorKim, T. -Y.-
dc.contributor.authorKim, W. H.-
dc.contributor.authorYang, H. -K.-
dc.contributor.authorHeo, D. S.-
dc.contributor.authorBang, Yung-Jue-
dc.contributor.authorLee, K. -U.-
dc.contributor.authorChoe, K. -J.-
dc.contributor.authorKim, N. K.-
dc.date.accessioned2020-04-27T11:39:39Z-
dc.date.available2020-04-27T11:39:39Z-
dc.date.issued2009-03-
dc.identifier.citationBritish Journal of Cancer, Vol.100 No.5, pp.732-738-
dc.identifier.issn0007-0920-
dc.identifier.other91866-
dc.identifier.urihttps://hdl.handle.net/10371/165550-
dc.description.abstractThe aim of this study was to analyse the impact of epidermal growth factor receptor (EGFR), thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP), aurora kinase (ARK) A/B, and excision repair crosscomplementing gene 1 (ERCC1) on the efficacy of adjuvant chemotherapy with 5-fluorouracil and cisplatin (FP) after curative gastric resection. Normal and cancer tissue were separately obtained from gastrectomy samples of 153 patients with AJCC stage III-IV (M0) who subsequently treated with adjuvant FP chemotherapy. TS, DPD, TP, ERCC1, and ARK proteins were measured by immunohistochemistry (IHC). EGFR expression was investigated using a standardized IHC with the EGFR PharmDx assay. Amplification of EGFR gene was analysed using fluorescent in situ hybridisation (FISH). In multivariate analysis, stage, ratio of positive to removed lymph nodes, and EGFR expression were significant prognostic factors for overall survival. Patients with higher EGFR expression had better overall survival than those with lower expression (relative risk: 0.475 (95% confidence interval, 0.282-0.791, P = 0.005). Low EGFR expression might be a predictive marker for relapse in curative resected stage III-IV (M0) gastric cancer patients who received adjuvant FP chemotherapy.-
dc.subjectgastric cancer-
dc.subjectadjuvant chemotherapy-
dc.subjectpharmacogenetics-
dc.subjectepidermal growth factor receptor-
dc.subjectthymidine phosphorylase-
dc.subjectexcision repair cross-complementing gene 1-
dc.titleBiomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival-
dc.typeArticle-
dc.contributor.AlternativeAuthor방영주-
dc.identifier.doi10.1038/sj.bjc.6604936-
dc.citation.journaltitleBritish Journal of Cancer-
dc.identifier.scopusid2-s2.0-61749089272-
dc.citation.endpage738-
dc.citation.number5-
dc.citation.startpage732-
dc.citation.volume100-
dc.identifier.urlhttps://www.nature.com/articles/6604936-
dc.identifier.rimsid91866-
dc.identifier.sci000263905900010-
dc.description.isOpenAccessN-
dc.contributor.affiliatedAuthorBang, Yung-Jue-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse